Literature DB >> 16116339

Hemodynamic effect of intracoronary administration of levosimendan in the anesthetized pig.

E Grossini1, P P Caimmi, C Molinari, G Teodori, G Vacca.   

Abstract

In this study the hemodynamic effects of intracoronary injection of levosimendan in anesthetized pigs and the mechanisms involved were examined. In 12 anesthetized pigs instrumented for measurement of heart rate (HR), aortic blood pressure (ABP), central venous pressure (CVP), left ventricular end-diastolic blood pressure, left ventricular contractility and relaxation, and mean coronary blood flow (CBF), levosimendan has been injected into the left anterior descending coronary artery at doses corresponding to the ones commonly used in clinics as bolus administration but adapted to the measured CBF. In a further 9 pigs levosimendan has been administered after the blockade of alpha and beta adrenoceptors, muscarinic receptors, and coronary nitric oxide synthase (NOS) to investigate the action mechanism of the drug. The intracoronary bolus administration of doses of levosimendan corresponding to 12 and 24 microg/kg in 10 minutes exerted, respectively, CBF increases of 26.3% and 41.3% of the control values in the absence of changes in the other hemodynamic variables. The blockade of the autonomic nervous system did not prevent the coronary vasodilation, which was, however, abolished by the NOS inhibition. The intracoronary administration of levosimendan exerts positive effects on myocardial blood supply without changes in ABP, HR, CVP, or in myocardial kinetics. The coronary effects of levosimendan are related to NO production.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16116339     DOI: 10.1097/01.fjc.0000175435.41541.6f

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  4 in total

1.  Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial K(ATP) channel.

Authors:  E Grossini; C Molinari; P P Caimmi; F Uberti; G Vacca
Journal:  Br J Pharmacol       Date:  2009-01-16       Impact factor: 8.739

2.  Intracoronary Levosimendan during Ischemia Prevents Myocardial Apoptosis.

Authors:  Markus Malmberg; Tommi Vähäsilta; Antti Saraste; Juha W Koskenvuo; Jussi P Pärkkä; Kari Leino; Timo Laitio; Christoffer Stark; Aira Heikkilä; Pekka Saukko; Timo Savunen
Journal:  Front Physiol       Date:  2012-02-14       Impact factor: 4.566

3.  Beneficial impact of levosimendan in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials.

Authors:  Tiziana Bove; Andrea Matteazzi; Alessandro Belletti; Gianluca Paternoster; Omar Saleh; Daiana Taddeo; Roberto Dossi; Teresa Greco; Nikola Bradic; Ino Husedzinovic; Caetano Nigro Neto; Vladimir V Lomivorotov; Maria Grazia Calabrò
Journal:  Heart Lung Vessel       Date:  2015

Review 4.  Classical inotropes and new cardiac enhancers.

Authors:  John T Parissis; Dimitrios Farmakis; Markku Nieminen
Journal:  Heart Fail Rev       Date:  2007-06       Impact factor: 4.654

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.